XERS Xeris Biopharma Holdings, Inc.

8-K Current Report

Filed: February 27, 2026

Health Care

Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc. (XERS) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Patent infringement suit filed under Hatch-Waxman Act against two generic drug companies seeking to market generic RECORLEV (levoketoconazole)
• Filing triggers automatic 30-month FDA approval stay for the ANDAs, protecting RECORLEV exclusivity during litigation

+2 more insights

Other Xeris Biopharma Holdings, Inc. 8-K Filings

8-K Mar 2, 2026

Get deeper insights on Xeris Biopharma Holdings, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.